Overview

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Status:
Recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Renmin Hospital of Wuhan University

Treatments:

Capecitabine
Oxaliplatin